Abdominal adiposity: Early intervention and therapeutic options

Clinical Cornerstone

Volumn 9, Issue SUPPL.1, 2008, Pages

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CANNABINOID 1 RECEPTOR ANTAGONIST; CYTOKINE; INSULIN; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ANXIETY; ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET THERAPY; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; EXERCISE; GASTRIC BANDING; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MOOD DISORDER; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; SIDE EFFECT; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

EID: 52049092308     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(08)80004-X     Document Type: Article

References (45)

1. Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355 (2006) 763-778
2. Yusuf S., Hawken S., Ounpuu S., et al., for the INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 366 (2005) 1640-1649
3. Després J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
4. Van Gaal L.F., Mertens I.L., and De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
5. Balkau B., Deanfield J.E., Després J.P., et al. International Day for the Evaluation of Abdominal Obesity (IDEA): A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 116 (2007) 1942-1951
6. Korner J., and Aronne L.J. Pharmacological approaches to weight reduction: Therapeutic targets. J Clin Endocrinol Metab 89 (2004) 2616-2621
7. Anderson J.W., and Konz E.C. Obesity and disease management: Effects of weight loss on comorbid conditions [published correction appears in Obes Res. 2003;11:following the table of contents ]. Obes Res 9 Suppl 4 (2001) 326S-334S
8. Després J.P., Lemieux I., and Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 322 (2001) 716-720
9. Taksali S.E., Caprio S., Dziura J., et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: A determinant of an adverse metabolic phenotype. Diabetes 57 (2008) 367-371
10. Poirier P., Giles T.D., Bray G.A., et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss:An update of he 1997 merican Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113 (2006) 898-918
11. Zimmet P., Alberti K.G., Kaufman F., et al., for the IDF Consensus Group. The metabolic syndrome in children and adolescents -an IDF consensus report. Pediatr Diabetes 8 (2007) 299-306
12. Yki-Järvinen H. Fat in the liver and insulin resistance. Ann Med 37 (2005) 347-356
13. Scheen A.J. Management of the metabolic syndrome. Minerva Endocrinol 29 (2004) 31-45
14. Scheen A.J. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 63 (2003) 1165-1184
15. Anderson J.W., Kendall C.W., and Jenkins D.J. Importance of weight management in type 2 diabetes: Review with meta-analysis of clinical studies. J Am Coll Nutr 22 (2003) 331-339
16. Lee M., and Aronne L.J. Weight management for type 2 diabetes mellitus: Global cardiovascular risk reduction. Am J Cardiol 99 Suppl (2007) 66B-79B
17. Scheen A.J. The future of obesity: New drugs versus lifestyle interventions. Expert Opin Investig Drugs 17 (2008) 263-267
18. Scheen A.J., and Paquot N. Pharmacological treatment of obesity, food intake, and reversal of metabolic disorders. Curr Nutr Food Sci 3 (2007) 11-133
19. Janiszewski P.M., and Ross R. Physical activity in the treatment of obesity: Beyond body weight reduction. Appl Physiol Nutr Metab 32 (2007) 55-522
20. Scheen A.J. Integrated approach to treatment and prevention. In: Hofbauer K.G., Keller U., and Boss O. (Eds). Pharmacotherapy of Obesity. Options and Alternatives (2004), CRC Press, Boca Raton, Fla 449-463
21. Franz M.J., Bantle J.P., Beebe C.A., et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 25 (2002) 148-198
22. Feldeisen S.E., and Tucker K.L. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 32 (2007) 46-60
23. Dansinger M.L., Tatsioni A., et al. Meta-analysis: The effect of dietary counseling for weight loss. Ann Intern Med 147 (2007) 41-50
24. Blair S.N., and Church T.S. The fitness, obesity, and health equation: Is physical activity the common denominator?. JAMA 292 (2004) 1232-1234
25. Kay S.J., and Fiatarone Singh M.A. The influence of physical activity on abdominal fat: A systematic review of the literature. Obes Rev 7 (2006) 183-200
26. Moro C., Bajpeyi S., and Smith S.R. Determinants of intramyo-cellular triglyceride turnover: Implications for insulin sensitivity. Am J Physiol Endocrinol Metab 294 (2008) E203-E213
27. McTigue K.M., Harris R., Hemphill B., et al. Screening and interventions for obesity in adults: Summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 139 (2003) 933-949
28. Bays H., and Dujovne C.A. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 88 (2006) 144-156
29. Dunican K.C., Desilets A.R., and Montalbano J.K. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother 41 (2007) 1445-1455
30. Li Z., Maglione M., Tu W., et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med 142 (2005) 532-546
31. Padwal R.S., and Majumdar R. Drug treatments or besity: Orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
32. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XXENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004;227:8856]. Diabetes Care 27 (2004) 155-161
33. Chanoine J.-P., Hampl S., Jensen C., et al. Effect of orlistat on weight and body composition in obese adolescents. A randomized controlled trial. JAMA 293 (2005) 22-2883
34. James W.P., Astrup A., Finer N., et al., for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356 (2000) 2119-2125
35. Torp-Pedersen C., Caterson I., Coutinho W., et al., for the SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: An analysis from the SCOUT trial. Eur Heart J 28 (2007) 2915-2923
36. Godoy-Matos A., Carraro L., Vieira A., et al. Treatment of obese adolescents with sibutramine: A randomized, double-blind, controlled study. J Clin Endocrinol Metab 90 (2005) 1460-1465
37. Pagotto U., Marsicano G., Cota D., et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100
38. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18 (2007) 27-37
39. Van Gaal L., Pi-Sunyer X., Després J.P., et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl 2 (2008) S229-S240
40. Després J.P., Golay A., and Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
41. Scheen A.J., Finer N., Hollander P., et al., for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 368 (2006) 1660-1672
42. Nissen S.E., Nicholls S.J., Wolski K., et al., for the STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. The STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560
43. Klein S., Fontana L., Young V.L., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary artery disease. N Engl J Med 33 (2004) 25-57
44. Thörne A., Lönnqvist F., Apelman J., et al. A pilot study of long-tt effects of a novel obesity treatment: Omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 26 (2002) 11-199
45. Sjöström L., Narbro K., Sjöström C.D., et al., for the Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007) 741-752